NEW YORK – GeneproDx, a Santiago, Chile-based startup, is developing a multiplex quantitative PCR assay that it believes will help patients at risk of thyroid cancer avoid unnecessary surgery.
Publishing a pair of validation studies earlier this month on the firm’s ThyroidPrint assay, US and Chilean researchers showed they could successfully predict benign thyroid nodules with a sensitivity of 90 to 91 percent and a specificity of 87 to 89 percent.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.